Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Le Scodan, Romuald ^a   Ali, David ^a   Stevens, Denise ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IRIDIUM 192;

ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; HUMAN; MASTECTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSTOPERATIVE CARE; QUALITY OF LIFE; RISK REDUCTION; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; ADJUVANT THERAPY; ANIMAL; BREAST TUMOR; DISEASE FREE SURVIVAL; EUROPE; FEMALE; METHODOLOGY; MORTALITY; ONCOLOGY; PATHOLOGY; RADIOTHERAPY; TREATMENT OUTCOME;

ANIMALS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 78349295710     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-630     Document Type: Article

References (61)

1. Sant M. Differences in stage and therapy for breast cancer across Europe. Int J Cancer 2001, 93:894-901. 10.1002/ijc.1408, 11519054.
2. Ries LA, Eisner MP, Kosary CL, et al. Seer cancer statistics review, 1975-2002. accessed on 2009., http://seer.cancer.gov/csr/1975_2002/
3. American Cancer Society's Breast Cancer Facts & Figures 2007-2008. accessed on 2009., http://www.cancer.org
4. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004, 9:617-632. 10.1634/theoncologist.9-6-617, 15561806.
5. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998, 339:974-984. 10.1056/NEJM199810013391407, 9753714.
6. Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006, 13:776-782. 10.1245/ASO.2006.03.033, 16614878.
7. Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2009, 115:7-12. 10.1007/s10549-008-0101-7, 18581232.
8. Blanchard DK, Shetty PB, Hilsenbeck SG, et al. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008, 247(5):732-738. 10.1097/SLA.0b013e3181656d32, 18438108.
9. Cady B, Nathan NR, Michaelson JS, et al. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol 2008, 15:3384-3395. 10.1245/s10434-008-0085-x, 18726129.
10. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis. Ann Surg Oncol 2007, 14:3345-3351. 10.1245/s10434-007-9527-0, 17687611.
11. Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol 2007, 14:2187-2194. 10.1245/s10434-007-9438-0, 17522944.
12. Hazard HW, Gorla SR, Kim J, Scholtens D. Surgical resection of the primary tumor in stage IV breast cancer and survival. Cancer 2008, 113:2011-19. 10.1002/cncr.23870, 18780312.
13. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery 2002, 132:620-626. 10.1067/msy.2002.127544, 12407345.
14. Le Scodan R, Stevens D, Brain E, et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009, 27:1375-1381. 10.1200/JCO.2008.19.5396, 19204198.
15. Rao R, Feng L, Kuerer HM, et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008, 15:1696-1702. 10.1245/s10434-008-9830-4, 18357493.
16. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006, 24:2743-2749. 10.1200/JCO.2005.04.2226, 16702580.
17. Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009, 35(11):1146-51.
18. Shien T, Kinoshita T, Shimizu C, et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep 2009, 21:827-832.
19. Leung AM, Vu HN, Nguyen KA, et al. Effects of Surgical Excision on Survival of Patients with Stage IV Breast Cancer. J Surg Res 2010, 161(1):83-8. 10.1016/j.jss.2008.12.030, 19375721.
20. Bourgier C, Khodari W, Vataire AL, et al. Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiother Oncol 2010,
21. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659. 10.1056/NEJMoa003013, 11759643.
22. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970. 10.1016/S0140-6736(01)06103-7, 11583750.
23. Hallissey MT, Allum WH, Roginski C, Fielding JW. Palliative surgery for gastric cancer. Cancer 1988, 62:440-444. 10.1002/1097-0142(19880715)62:2<440::AID-CNCR2820620232>3.0.CO;2-N, 2454725.
24. Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004, 139:961-966. 10.1001/archsurg.139.9.961, 15381613.
25. Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be?. Arch Surg 2000, 135:530-534. 10.1001/archsurg.135.5.530, 10807276.
26. Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004, 136:650-659. 10.1016/j.surg.2004.02.012, 15349115.
27. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000, 19:42-48. 10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO;2-M, 10883023.
28. Fehm T, Sagalowsky A, Clifford E, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002, 8:2073-2084.
29. Falkson G, Gelman R, Falkson CI, et al. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991, 9:2153-2161.
30. Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983, 1:776-786.
31. Nash CH, Jones SE, Moon TE, et al. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 1980, 46:2380-2388. 10.1002/1097-0142(19801201)46:11<2380::AID-CNCR2820461113>3.0.CO;2-M, 6449280.
32. Vincent MD, Powles TJ, Skeet R, et al. An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. Eur J Cancer Clin Oncol 1986, 22:1059-1065. 10.1016/0277-5379(86)90006-4, 3780813.
33. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
34. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430. 10.1200/JCO.2005.08.140, 15735118.
35. Caras I, Grigorescu A, Stavaru C, et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004, 53:1146-1152. 10.1007/s00262-004-0556-2, 15185014.
36. Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004, 64:2205-2211. 10.1158/0008-5472.CAN-03-2646, 15026364.
37. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999, 353:1641-1648. 10.1016/S0140-6736(98)09201-0, 10335782.
38. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337:949-55. 10.1056/NEJM199710023371401, 9395428.
39. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956-962. 10.1056/NEJM199710023371402, 9309100.
40. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
41. Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995, 13:2869-2878.
42. Coffey JC, Wang JH, Smith MJ, et al. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003, 4:760-768. 10.1016/S1470-2045(03)01282-8, 14662433.
43. Demicheli R, Retsky MW, Hrushesky WJ, et al. The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008, 19:1821-1828. 10.1093/annonc/mdn386, 18550576.
44. Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001, 65:217-224. 10.1023/A:1010626302152, 11336243.
45. Retsky M, Bonadonna G, Demicheli R, et al. Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004, 6:R372-R374. 10.1186/bcr804, 468653, 15217504.
46. Dubray B, Mazeron JJ, Simon JM, et al. Time factors in breast carcinoma: influence of delay between external irradiation and brachytherapy. Radiother Oncol 1992, 25:267-272. 10.1016/0167-8140(92)90246-Q, 1480772.
47. Mazeron JJ, Simon JM, Crook J, et al. Influence of dose rate on local control of breast carcinoma treated by external beam irradiation plus iridium 192 implant. Int J Radiat Oncol Biol Phys 1991, 21:1173-1177. 10.1016/0360-3016(91)90273-7, 1938515.
48. Fourquet A, Campana F, Mosseri V, et al. Iridium-192 versus cobalt-60 boost in 3-7 cm breast cancer treated by irradiation alone: final results of a randomized trial. Radiother Oncol 1995, 34:114-120. 10.1016/0167-8140(94)01492-L, 7597209.
49. Dubois JB, Salomon A, Gary-Bobo J, et al. Exclusive radical radiation therapy in breast carcinoma. Radiother Oncol 1991, 20:24-29. 10.1016/0167-8140(91)90108-S, 2020752.
50. Van Limbergen E, Van der SE, Van den BW, et al. Local control of operable breast cancer after radiotherapy alone. Eur J Cancer 1990, 26:674-679. 10.1016/0277-5379(90)90115-A, 2168190.
51. Harris JR, Sawicka J, Gelman R, Hellman S. Management of locally advanced carcinoma of the breast by primary radiation therapy. Int J Radiat Oncol Biol Phys 1983, 9:345-349.
52. Sheldon T, Hayes DF, Cady B, et al. Primary radiation therapy for locally advanced breast cancer. Cancer 1987, 60:1219-1225. 10.1002/1097-0142(19870915)60:6<1219::AID-CNCR2820600610>3.0.CO;2-2, 3621108.
53. Spanos WJ, Montague ED, Fletcher GH. Late complications of radiation only for advanced breast cancer. Int J Radiat Oncol Biol Phys 1980, 6:1473-1476.
54. Courdi Adel, Ortholan C, Hannoun-Lévi JM, et al. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol 2006, 79:156-61. 10.1016/j.radonc.2006.04.005, 16698099.
55. Pierquin B, Huart J, Raynal M, et al. Conservative treatment for breast cancer: long-term results (15 years). Radiother Oncol 1991, 20:16-23. 10.1016/0167-8140(91)90107-R, 2020751.
56. Whelan TJ, Kim DH, Sussman J. Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol 2008, 18:257-264. 10.1016/j.semradonc.2008.04.008, 18725113.
57. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520. 10.1056/NEJMoa0906260, 20147717.
58. Local surgery for metastatic breast cancer. ClinicalTrials.gov Identifier: NCT00557986 , http://clinicaltrials.gov/ct2/show/NCT00557986
59. Soran A, Ozbas S, Kelsey SF, Gulluoglu BM. Randomiezd trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (protocol MF07-01): a study of Turkish Federation of the National Societies for breast diseases. Breast J 2009, 15:399-403. 10.1111/j.1524-4741.2009.00744.x, 19496782.
60. Assessing impact of loco-regional treatment on survival in metastatic breast cancer at presentation. ClinicalTrials.gov Identifier: NCT00193778 , http://clinicaltrials.gov/ct2/show/NCT00193778
61. Parmar V, Hawaldar RW, Pandey N, et al. Surgical removal of primary tumor in women with metastatic breast cancer--Is it really justified?. ASCO breast cancer symposium 2009, abstract 323.